Drugs with anticholinergic properties: a current perspective on use and safety

被引:126
|
作者
Gerretsen, Philip [1 ]
Pollock, Bruce G. [2 ]
机构
[1] Univ Toronto, Dept Psychiat, Toronto, ON M5S 1A1, Canada
[2] Univ Toronto, Div Geriatr Psychiat, Fac Med, Dept Psychiat, Toronto, ON M5S 2S1, Canada
关键词
anticholinergic adverse effects; anticholinergic drugs; anticholinergic safety monitoring; anticholinergic toxicity; cholinergic neurotransmission; drug safety; CENTRAL-NERVOUS-SYSTEM; NICOTINIC ACETYLCHOLINE-RECEPTORS; OVERACTIVE BLADDER; COGNITIVE IMPAIRMENT; SERUM LEVELS; CARDIAC-ARRHYTHMIAS; ALZHEIMERS-DISEASE; TROSPIUM CHLORIDE; BASAL FOREBRAIN; BEERS CRITERIA;
D O I
10.1517/14740338.2011.579899
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Introduction: Many commonly used drugs have primary or secondary anticholinergic effects contributing to adverse outcomes ranging from mild-to-severe to potentially lethal. Anticholinergic adverse effects frequently occur with medications prescribed with other intended mechanisms of action, including antihistamines, antidepressants, and antipsychotics. Anticholinergic drugs are also the principal treatments of clinical conditions, such as urinary incontinence, that tend to occur in the elderly. Older patients and those with mental illness are particularly vulnerable to the adverse neuropsychiatric effects of anticholinergics as they may already have cognitive impairment. Areas covered: Medline and Pubmed literature searches (1966 - the present) were performed using 'anticholinergic' and 'drug safety'. Abstracts were assessed and references scanned for appropriate articles. Here, the authors i) describe the neural pathways of the cholinergic system; ii) outline the main clinical uses and adverse effects of anticholinergic agents with a focus on cognitive impairment; and iii) discuss anticholinergic safety monitoring. Expert opinion: Prescribers need to be vigilant for adverse anticholinergic effects, particularly in older patients. The symptoms may range from subtle cognitive impairment to delirium and may be due to the cumulative effect of multiple medications of modest antimuscarinic activity. The Anticholinergic Drug Scale and tables listing drugs with known anticholinergic properties may help in guiding clinical decision-making to reduce anticholinergic burden.
引用
收藏
页码:751 / 765
页数:15
相关论文
共 50 条
  • [21] Association between the use of anticholinergic antiparkinson drugs and safety and receptor drug-binding profiles of antipsychotic agents
    Pål Gjerden
    Lars Slørdal
    Jørgen G. Bramness
    European Journal of Clinical Pharmacology, 2009, 65 : 1229 - 1235
  • [22] Association between the use of anticholinergic antiparkinson drugs and safety and receptor drug-binding profiles of antipsychotic agents
    Gjerden, Pal
    Slordal, Lars
    Bramness, Jorgen G.
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2009, 65 (12) : 1229 - 1235
  • [23] Current perspective on antithrombin drugs
    McGregor, JL
    PATHOPHYSIOLOGY OF HAEMOSTASIS AND THROMBOSIS, 2002, 32 : 29 - 35
  • [24] Anticholinergic drugs use and risk of hip fracture in geriatric patients
    Kose, Eiji
    Hirai, Toshiyuki
    Seki, Toshiichi
    GERIATRICS & GERONTOLOGY INTERNATIONAL, 2018, 18 (09) : 1340 - 1344
  • [25] Concomitant use of anticholinergic drugs in a large cohort of geriatric patients
    Pfistermeister, B.
    Tuemena, T.
    Gassmann, K. -G.
    Maas, R.
    Fromm, M. F.
    NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY, 2016, 389 (01) : S21 - S21
  • [26] Use of anticholinergic drugs and impact on cognition in Parkinson's disease
    Ehrt, U.
    Broich, K.
    Larsen, J. P.
    Ballard, C.
    Dag, A.
    MOVEMENT DISORDERS, 2009, 24 : S220 - S221
  • [27] HAZARDS IN THE USE OF ANTICHOLINERGIC DRUGS IN THE MANAGEMENT OF PEPTIC ULCER DISEASE
    ROTH, JLA
    WECHSLER, RL
    BOCKUS, HL
    GASTROENTEROLOGY, 1956, 31 (05) : 493 - 499
  • [28] Increased Risk of Dementia by Long Term Use of Anticholinergic Drugs
    Puellen, R.
    Dovjak, P.
    ZEITSCHRIFT FUR GERONTOLOGIE UND GERIATRIE, 2015, 48 (06): : 571 - 571
  • [29] THE USE OF ANTICHOLINERGIC DRUGS FOR SMOKING CESSATION - A PILOT-STUDY
    BACHYNSKY, N
    INTERNATIONAL JOURNAL OF THE ADDICTIONS, 1986, 21 (07): : 789 - 805
  • [30] Use of toxicogenomics in drug safety evaluation: Current status and an industry perspective'
    Vahle, John L.
    Anderson, Ulf
    Blomme, Eric A. G.
    Hoflack, Jean-Christophe
    Stiehl, Daniel P.
    REGULATORY TOXICOLOGY AND PHARMACOLOGY, 2018, 96 : 18 - 29